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Abstract 
On the surface of the eye, both the cornea and conjunctiva are restricting ocular absorption of topically 
applied drugs, but barrier contributions of these two membranes have not been systemically compared. 
Herein, we studied permeability of 32 small molecular drug compounds across an isolated porcine cornea 
and built a quantitative structure-property relationship (QSPR) model for the permeability. Corneal drug 
permeability (data obtained for 25 drug molecules) showed a 52-fold range in permeability (0.09-4.70 x 
10-6 cm/s) and the most important molecular descriptors in predicting the permeability were hydrogen 
bond donor, polar surface area and halogen ratio. Corneal permeability values were compared to their 
conjunctival drug permeability values.  Ocular drug bioavailability and systemic absorption via 
conjunctiva were predicted for this drug set with pharmacokinetic simulations. Drug bioavailability in 
the aqueous humour was simulated to be less than 5% and trans-conjunctival systemic absorption was 
34-79% of the dose. Loss of drug across the conjunctiva to the blood circulation restricts significantly 
ocular drug bioavailability and, therefore, ocular absorption does not increase proportionally with the 












QSPR (quantitative structure-property relationship) 
LogD7.4 (the logarithm of the octanol-water distribution coefficient at pH 7.4)  
Papp, CJ (conjunctival permeability) 
Papp, CO (corneal permeability) 
PSA (polar surface area) 




































Eye drops are the most commonly used drug formulation in ophthalmology (Urtti, 2006). They are widely 
used in the treatment of glaucoma, dry eye disease, infections and inflammatory conditions of the anterior 
part of the eye. Cornea and conjunctiva are the major tissue barriers that limit ocular drug absorption 
after instillation of eye drops. Cornea represents a tight barrier and route for drug absorption into the 
aqueous humour of the eye; the most commonly used sampling site in ocular bioavailability studies 
(Ahmed and Patton, 1987, 1985; Doane et al., 1978). Although, the conjunctival epithelium has inter-
cellular tight junctions, it is leakier than the cornea (Ahmed and Patton, 1987; Huang et al., 1989; 
Hämäläinen et al., 1997) and has a surface area 17 times larger than cornea (Watsky et al., 1988). 
Conjunctiva is a route for ocular drug absorption, particularly to the iris and ciliary body (Ahmed and 
Patton, 1987, 1985; Shikamura et al., 2016), but most trans-conjunctival permeation leads to systemic 
drug absorption from the conjunctival sac (Urtti et al., 1994, 1985).    
 
Cornea is composed of three main layers: the outermost epithelium, the middle stroma, and the innermost 
endothelium. The epithelium has tight junctions in the most superficial cells and it represents the rate-
limiting barrier (Huang et al., 1989, 1983) that restricts drug permeation, especially for hydrophilic and 
large molecules (Ahmed et al., 1987; Huang et al., 1989). Hydrophilic and highly permeable stroma may 
limit permeation of very lipophilic drugs that show restricted partitioning from the epithelium to the 
stroma (Huang et al., 1983; Prausnitz and Noonan, 1998). The corneal endothelium is not considered to 
be a significant barrier in ocular drug absorption (Huang et al., 1983; Prausnitz and Noonan, 1998). The 
conjunctiva covers the inner side of the eyelids and the anterior part of the sclera thus serving as a barrier 
between lacrimal fluid and the eye (bulbar conjunctiva), as well as the blood circulation (palpebral 
conjunctiva). The conjunctiva is a semi-transparent mucous membrane, composed of multi-layered 
epithelium on top of vascularised connective tissue (Dartt, 2002).  
 
After eye drop instillation, the drug is eliminated from the lacrimal fluid by drainage of extra solution, 
induced lacrimation, tear turnover, and conjunctival absorption (Lee and Robinson, 1979; Thombre and 
Himmelstein, 1984; Urtti et al., 1994, 1985). The pre-corneal loss factors and the corneal barrier limit 
ocular drug absorption, resulting in low bioavailability in the anterior chamber (typically less than 5%) 












On the other hand, much larger fraction of the instilled dose will enter systemic blood circulation through 
conjunctiva and nasal mucosa (Chang and Lee, 1987; Urtti et al., 1994, 1985; Urtti and Salminen, 1993). 
For example, 70-80% of timolol dose absorbs systemically (Chang and Lee, 1987; Urtti et al., 1985) and 
this caused systemic adverse drug effects (Nelson et al., 1986).  
 
In order to develop new ocular drugs and drug formulations it is important to understand drug 
permeability at the cornea and conjunctiva, and their impact on ocular drug absorption. We published a 
study on permeability of 30 drugs in the isolated porcine conjunctivas and built a predictive quantitative 
structure-property relationship (QSPR) model for the permeability (Ramsay et al., 2017), but the field 
still lacks such predictive models for corneal drug permeability that are based on experimental data with 
a large set of drug compounds using similar test method. Ocular pharmacokinetic rabbit models have 
been published for topical eye drops (Deng et al., 2016; Grass and Lee, 1993; Himmelstein et al., 1978; 
Lee and Robinson, 1979; Makoid and Robinson, 1979; Miller et al., 1981; Thombre and Himmelstein, 
1984), but these models are based on absorption of individual compounds and systematic comparisons 
of corneal and conjunctival drug permeability with wider chemical space and related pharmacokinetic 
models are missing. Such information would be useful in ocular drug development. We studied the 
corneal drug permeability across ex vivo porcine cornea and constructed a QSPR model for the corneal 
drug permeability. Additionally, the corneal and conjunctival (Ramsay et al., 2017) drug permeabilities 
were utilized to predict their impact on ocular and systemic drug absorption from the ocular surface.  
 
 
2. Materials and methods 
 
2.1 Compounds and sample preparation 
We used 32 compounds that were in the cassette dose described earlier (Ramsay et al., 2017).  The stock 
solutions were prepared, in either phosphate-buffer saline (PBS) or dimethyl sulfoxide (DMSO), at two 
different concentrations (1 and 10 mg/mL), based on the analytical quantitation limits. The stock 
solutions of each drug were combined and diluted with BSS Plus (Alcon Laboratories, TX, USA). The 
final drug concentration in the apical side of the diffusion chamber was either 2 or 20 µg/mL. The 
following ten drugs had a higher final concentration (20 μg/mL): aztreonam, bromfenac, dexamethasone, 
diclofenac, indomethacin, levocabastine, methazolamide, prednisolone, quinidine, and tizanidine; 













2.2 Tissue preparation 
The porcine eyes were obtained from a local slaughterhouse and kept on ice in Dulbecco’s phosphate-
buffered saline (DPBS, pH 7.4) (Gibco, Invitrogen, NY, USA) during transport to the laboratory. The 
cornea was isolated and used in the permeability study. First, a small cut was made with the scalpel at 
the limbus, which separates the cornea from the conjunctiva. Then, the cornea was dissected from the 
eyeball by cutting along the limbus. During the preparation care was taken to avoid drying of the tissue, 
by applying on the cornea balanced salt solution, containing glutathione, glucose, bicarbonate, and 
electrolytes (BSS Plus, pH 7.4 and osmolarity 305 mOsm/kg) (Alcon Laboratories, TX, USA). 
 
2.3 Permeability study 
The isolated porcine cornea was first placed between two silicon rings (circular aperture of 0.64 cm2). 
Then the silicon-cornea-silicon set up was placed in a vertical Ussing/diffusion chamber (Harvard 
Apparatus, MA, USA). Both the apical and basolateral side of the diffusion chamber were filled with 5.5 
mL or 6.5 mL pre-warmed BSS Plus buffer, respectively. The chambers were equipped with gas tubing 
providing the cornea with 5% CO2 in O2, at a low speed. A circulating water bath (Haake DC10-W26/B, 
Thermo Scientific, MA, USA) was connected to a heat block surrounding the chambers and maintaining 
the temperature at 35 °C. The chambers were also equipped with electrode caps and glass barrel Ag/AgCl 
electrodes (NaviCyte Electrodes, Harvard Apparatus, MA, USA), which were connected to a voltage-
current clamp (VCC MC 6, Physiologic Instruments, CA, USA), for the measurement of trans-epithelial 
electrical resistance (TER).  The permeability experiments were started by removing 550 µL from the 
apical side and replacing with the same volume of the cassette dose. The initial donor concentration on 
the apical side (referring to the surface of the eye) was either 2 or 20 µg/mL, depending on the drug. 
Samples of 500 µL were then withdrawn from the basolateral side (referring to the aqueous humour side) 
at 15, 30, 45, 60, 75, 90, 120, 150,180, 210, 240, 270, 300, 330 and 360 min. The removed sample was 
replaced with the same volume of fresh BSS Plus buffer. At the beginning and at the end of the 
experiment a sample of 40 µL was withdrawn from the apical side of the diffusion chamber for Papp 
calculations.  Samples were stored in – 20 °C until LC-MS/MS analysis.  
 
The apparent permeability coefficient (Papp) of the drug across the cornea was calculated as: Papp, CJ 












is the initial donor concentration (ng/cm3), and A the area of the exposed tissue (0.64 cm2).  The sink 
conditions were maintained during the permeability experiments, the drug concentration of the receiver 
site was <10% of that on the donor site.  
 
2.4 Quantitative analysis 
The drug permeability was analysed with a LC-MS/MS system, which consisted of an Agilent 1290 
series liquid chromatograph and an Agilent 6495 triple-quadrupole mass spectrometer (Agilent 
Technologies, Inc., USA) with electrospray ionization. For more detailed information please refer to 
Ramsay et al., 2017. 
 
2.5 Multivariate QSPR model generation 
A corneal drug permeability QSPR model was generated with multivariate analysis tools, composed of 
principal component analysis (PCA) and linear partial least square (PLS). For the model building, we 
used the apparent corneal permeability (Papp, CO) values of 25 small molecular drugs of the cassette dose 
and their 35 molecular descriptors.  
 
2.5.1 Molecular descriptors 
The 35 molecular descriptors were calculated based on the structure-data file format of 25 drugs of the 
cassette dose, using the ACDlabs® software (version 12, Advanced Chemistry Development, Inc., 
Toronto, Canada). The following  molecular descriptors were generated: molecular weight (MW);  pKa 
for the most acidic molecular form (pKa MA); pKa for the most basic molecular form (pKa MB); LogD 
at pH 5.5, 7.4, and 10; LogP; polar surface area (PSA); freely rotatable bonds (FRB); hydrogen bond 
donors (HBD); hydrogen bond acceptors (HBA); HBtot (HBD + HBA); rule of 5 (Rule5); molar 
refractivity (MR); molar volume (MV); parachor; index of refraction (IR); surface tension (Ste); density; 
polarizability; C ratio; N ratio; NO ratio; hetero ratio; halogen ratio; number of rings (Num Rings); 
number of aromatic rings; 3-, 4-, 5- and 6-membered rings; and percentage of ionized form (acid, basic, 
neutral or zwitterion) at pH 7.4 (Sol% A, B, N or Z (7.4)). 
 
2.5.2 Model Calibration and Building 
The QSPR model was calibrated and built using PCA and PLS, respectively (Simca ®, version 14.1, 












transformed. The PCA was used to visualize the chemical space of the small molecular drugs. An external 
test set was chosen and excluded for later model validation. The drugs in the external data set were chosen 
randomly after drugs representing extreme descriptor and permeability values were ignored. During 
model calibration descriptors with narrow variance were excluded aiming for PCA model with a 
goodness of fit R2 and predictability Q2 higher than 0.5. In the PLS, the relationship between the 
logarithm of the corneal permeability (logPapp, CO) and the remaining molecular descriptors of the drug 
set (training set) were modelled. Descriptors with a small influence on the model were excluded during 
the modelling based on the plots of PLS weight, coefficient, and variable importance for the projection.  
 
2.5.3 Model validation and applicability domain 
The reliability of the predictive PLS model was validated by internal and external validation. During the 
PLS model building the training set was internally validated by cross-validation (Q2Y), which meant that 
one-seventh of the data was left out for the cross-validation. The generated PLS model was externally 
validated by determining the regression coefficient, when plotting the predicted versus the experimental 
values of the external test set (Qe
2). An accurate model shows values higher than 0.5 for Q2Y and Qe
2. 
Additionally, the Y-randomization test was conducted to prove the robustness of the model. The 
generated QSPR model can only be used for compounds, which have a similar chemical space as that of 
the training set drugs.  
 
2.6 Prediction of ocular and systemic drug absorption from the ocular surface 
The impact of corneal and conjunctival drug permeability on drug absorption to the aqueous humour and 
the systemic blood circulation were calculated based on corneal and conjunctival clearance (Cl), as well 
as, tear flow rate (Q). However, we did not taking into account solution drainage and induced lacrimation 
that may take place after eye drop instillation (Chrai et al., 1973; Conrad et al., 1978). Corneal and 
conjunctival clearance values (Cl cornea, Cl conjunctiva) were calculated by multiplying the apparent 
permeability in the cornea (Papp, CO ; present study) or conjunctiva (Papp, CJ ; Ramsay et al., 2017) for each 
drug with either the corneal surface area (1.04 cm2) or half of the conjunctival surface area (8.83 cm2), 
respectively. Half of the conjunctival surface area was used, because we assumed that the applied eye 
drop is quickly draining to the lower fornix where the drug is absorbed, rather than in the upper fornix. 
The human tear flow rate (Q tear) was reported in the literature as 1.2 μL/min (Lee and Robinson, 1986). 













Topical clearance = Cl cornea + Cl conjunctiva + Q tear    
 (1) 
 
Then, trans-corneal drug absorption was estimated as bioavailability (F) in the aqueous humour as: 
 
  F aqueous humour (%) = Cl cornea / Topical clearance    
 (2) 
 
Trans-conjunctival drug absorption to the systemic blood circulation was estimated as: 
 
  F conjunctival systemic (%) = Cl conjunctiva / Topical clearance   (3) 
 
We assumed that the drug is evenly distributed in the tear fluid, and that the amount of drug that crosses 
the conjunctiva will enter the systemic circulation. Drug elimination from the ocular surface in the tear 




3.1 Corneal drug permeability 
Drug permeability in the isolated porcine corneas varied over 52-fold range (0.09-4.70 x 10-6 cm/s) for 
25 small molecular drugs (Table 1). Concentrations of seven drugs in the cassette dose (acyclovir, 
cephalexin, ciprofloxacin, dorzolamide, ganciclovir, lornoxicam, and methotrexate) were below the limit 
of quantification and the calculation of their Papp values was not possible. Integrity of the corneas were 
confirmed by the solute permeability values (Papp, CO) and bioelectrical measurements (TER). The TER 
values were 372 ± 54 Ω x cm2 (n = 7) at the beginning and 917 ± 362 Ω x cm2 (n = 6) at the end of the 
permeability assays.  
 
Table 1. Compounds in the permeability studies. MW, LogD7.4, PSA and HBD molecular descriptors, 
experimental (± SD) and/ or predicted corneal permeability values, and the number (n) of isolated corneal 

















 (10-7 cm/s) 
Predicted 
Papp,CO 
 (10-7 cm/s) 
n 
Acetazolamide 222.3 -0.69 151.7 3 0.00 2.27 ± 0.70  1.74 3 
Ampicillin * 349.4 -1.84 138.0 4 0.00 1.89 ± 0.24 1.37 3 
Atenolol 266.3 -1.76 84.6 4 0.00 1.72 ± 0.87  2.00 7 
Atropine 289.4 -1.09 49.8 1 0.00 5.64 ± 2.15  7.61 7 
Aztreonam 435.4 -4.32 238.2 5 0.00 1.02 ± 0.49  0.66 3 
Betaxolol 307.4 0.43 50.7 2 0.00 15.80 ± 10.70  5.50 7 
Brinzolamide 383.5 4.19 163.8 3 0.00 1.36 ± 0.35  1.64 3 
Bromfenac  334.2 -1.04 80.4 3 0.05 3.99 ± 2.67  4.01 5 
Carteolol 292.4 -0.74 70.6 3 0.00 1.43 ± 0.49  3.13 7 
Dexamethasone 
* 
392.5 2.03 94.8 3 0.04 1.57 ± 0.75  3.20 7 
Diclofenac  296.2 1.44 49.3 2 0.11 6.20 ± 6.49  12.03 5 
Fluconazole * 306.3 0.45 81.7 1 0.09 9.97 ± 4.50  9.76 7 
Indomethacin 357.8 0.98 68.5 1 0.04 5.03 ± 3.62  7.85 5 
Ketorolac 255.3 -0.34 59.3 1 0.00 3.49 ± 0.72  6.65 4 
Levocabastine 420.5 1.55 64.3 1 0.03 4.08 ± 2.16  7.82 4 
Lincomycin 406.5 -0.36 147.8 5 0.00 0.90 ± 0.32  0.96 7 
Methazolamide  236.3 -0.21 138.9 2 0.00 4.74 ± 1.66  2.54 7 
Nadolol  309.4 -1.54 82.0 4 0.00 1.22 ± 0.41  2.05 7 
Pilocarpine 208.3 -0.39 44.1 0 0.00 17.86 ± 6.02 11.38 7 
Pindolol * 248.3 -0.5 57.3 3 0.00 7.54 ± 4.79  3.68 4 
Prednisolone 360.4 1.63 94.8 3 0.00 2.03 ± 0.89  2.50 4 
Propranolol 259.3 0.79 41.5 2 0.00 15.18 ± 14.66 6.42 4 
Quinidine * 324.4 0.98 45.6 1 0.00 8.68 ± 6.25  8.14 7 
Tizanidine  253.7 2.04 90.4 2 0.06 47.04 ± 17.57   4 
Voriconazole  349.3 1.21 76.7 1 0.12 31.68 ± 15.34  12.52 4 
a PSA is calculated based on topological PSA  
b Halogen ratio, is calculated as the sum of all halogens (F, Cl, Br, I) divided by the sum of all heavy 
atoms (excluding hydrogen)  
* external data set 
 
 
3.2 Multivariate QSPR model for corneal drug permeability  
The QSPR model was generated for 24 drugs excluding tizanidine that was an outlier and showed to bias 
the model in preliminary studies. The QSPR model generation stages and results are shown in Figure 1. 
 












A complete list of the 24 drugs and 35 molecular descriptors that were used for QSPR modelling are 
found in the Supplementary data A. The small molecular drug set represent a broad chemical space: MW 
of 208.3-435.4 Da, LogD7.4 from -4.3 to +4.2, PSA of 41.5-238.2 Å
2, HBtot (HBA + HBD) of 4-18, and 
halogen ratio of 0-0.12. 
 
Before model calibration (PCA) an external test set of five drugs (ampicillin, dexamethasone, 
fluconazole, pindolol, and quinidine) was removed. In the present study, an internal test set of drugs was 
not used, due to the small set of drugs available. The PCA analysis was conducted with the remaining 19 
drugs, and the following five descriptors were removed due to low variance: 3-, 4- and, 5-membered 
rings, number of rings, and percentage of ionized species. A statistically significant PCA model was 
obtained (R2 of 0.87 and Q2 of 0.57, 30 descriptors) with four principal components explaining the 
variance of the descriptor space. The chemical space of the training set is illustrated with two principal 
components in Figure 2. The principal components explained 38% t1  and 22% t2 of the variance in 
the set, respectively.  
 
3.2.2 Model building (PLS), validation and applicability  
The training set of 19 drugs was used to generate a predictive model for corneal drug permeability. The 
final model showed that polar surface area (PSA), hydrogen bond donor (HBD) and halogen ratio were 
essential in permeability prediction (Table 2). The model showed acceptable statistical significance, with 
goodness of fit R2X of 0.62 and R2Y of 0.69, and goodness of prediction Q2Y of 0.63. The regression 
coefficient of the predicted versus experimental corneal permeability for the external test set drugs (Qe2) 
was 0.66 (Fig. 3). The model predicted the external test set with a mean fold error of 1.5. The robustness 
of the model, tested with Y-randomization test, was good (Supplementary data B). The model can be 
applied for predicting corneal drug permeability of new compounds with a similar chemical space as that 
of the training set drugs (Supplementary data A). 
 
Table 2. The linear partial least square (PLS) model for the corneal drug permeability including 
validation results.  













LogPapp, CO = -4.6823 - 







0.62 0.69 0.63 0.66 Ok 
a R2X and R2Y describe the goodness of fit of the training set  
b Q2Y describe the goodness of prediction of the model 
c Qe2 is the regression coefficient of predicted versus experimental values for the external test set 
 
3.3 Role of corneal and conjunctival permeability in ocular and systemic drug absorption from the 
ocular surface  
Based on the conjunctival drug permeability and simulations drug elimination from tear fluid across the 
conjunctiva had a great impact on bioavailability to the aqueous humour and trans-conjunctival systemic 
bioavailability. Based on the calculations, trans-conjunctival permeation of the test drugs is expected to 
lead to systemic absorption of 34-79% of the drug dose. Only 0.3-4.4% of the applied dose reaches the 
aqueous humour via trans-corneal permeation (Fig. 4). Tear flow removes 18-66% of the dose to the 
nasal cavity and possibly further. It is noteworthy that the increase in the corneal drug permeability did 
not result in a proportional increase of ocular drug bioavailability, because the increased corneal 
permeability is associated with higher permeation in the conjunctiva that leads to drug loss to the systemic 
blood circulation. More than 50-fold increase in corneal drug permeability resulted in only 14-fold 
increase in drug absorption to the aqueous humour (Fig. 4). The clearance and bioavailability values of 




Small molecular drug compounds are widely used as eye drops to treat anterior segment diseases (Urtti, 
2006). In this study we show that the drug permeability in isolated porcine cornea of the presented drug 
set varies over 52-fold range. Broad range of permeability values reflects the tight barrier in the corneal 
epithelium (Ahmed et al., 1987; Huang et al., 1989, 1983; Hämäläinen et al., 1997). For example, 
hydrophilic lincomycin (0.90 ± 0.32 x 10-7 cm/s) permeated much slower across the cornea than 
lipophilic voriconazole (31.68 ± 15.34 x 10-7 cm/s). Most of the permeability studies are done with rabbit 
cornea that seems to be more permeable than the porcine (Kidron et al., 2010; Loch et al., 2012; Prausnitz 
and Noonan, 1998; Wang et al., 1991). For instance pindolol has a 14 times smaller permeability in the 












both thinner corneal epithelium and the whole cornea tissue of the rabbit compared to that of the porcine 
eye (Agarwal and Rupenthal, 2016). Relationship with the permeability in human cornea is difficult to 
assess because only very limited data is available from human cornea studies.   
 
Corneal drug permeability is known to be affected by drug properties, such as lipophilicity, molecular 
size, and charge (Ahmed et al., 1987; Brechue and Maren, 1993; Chien et al., 1990; Huang et al., 1989, 
1983; Liaw et al., 1992; Pescina et al., 2015; Schoenwald and Huang, 1983; Wang et al., 1991). Usually 
these studies have been performed with rabbit corneas and only a few compounds.  Some reports include 
larger data sets on corneal drug permeability, but they have been collected from different sources with 
variable research methods (Kidron et al., 2010; Prausnitz and Noonan, 1998). In the present study, 
corneal permeability values were generated for 25 compounds using identical experimental set up. This 
should minimize variation that is related to the methods. Statistically valid QSPR model was generated 
based on the permeation data, and polar surface area (PSA), hydrogen bond donor (HBD), and halogen 
ratio adequately predict the corneal permeation. PSA and HBD have an inverse effect on drug 
permeability across the cornea, whereas the halogen ratio has a positive effect. PSA and the ability to 
form hydrogen bonds are important descriptors also in drug permeation across the porcine conjunctiva 
(Ramsay et al., 2017), rabbit cornea (Kidron et al., 2010), and human intestine (Linnankoski et al., 2006; 
Winiwarter et al., 1998).  
 
Systematic quantitative comparison of porcine corneal and conjunctival permeation reveals that the 
cornea is 8.6 ± 4.4 times tighter barrier than the conjunctiva (Fig. 5). A similar pattern has been shown 
in studies with rabbit and bovine membranes (Ahmed et al., 1987; Huang et al., 1989; Hämäläinen et al., 
1997; Loch et al., 2012; Wang et al., 1991). However, the range of permeability values was narrower in 
the conjunctiva (8.5 fold) than in the cornea (52 fold).   
 
Pre-corneal flow (drainage, tear turnover) factors and permeability (cornea, conjunctiva) determine the 
overall ocular drug bioavailability. According to our simulations the trans-corneal drug bioavailability in 
the aqueous humour was less than 5% and, in many cases less than 1% (Fig. 4). The simulations are in 
line with in vivo rabbit experiments showing low bioavailability to the aqueous humour (< 5%) (Chrai 
and Robinson, 1974; Lazare and Horlington, 1975; Maurice and Mishima, 1984; Urtti et al., 1990) and 












and Salminen, 1993).  It is important to note that the increase in ocular bioavailability is less than the 
proportional increase in the corneal permeability, because both ocular absorption and systemic loss are 
increased for compounds with high membrane permeability.  
 
The simulations showed that a large fraction of the drug dose is eliminated to the systemic blood 
circulation across the conjunctiva (34-79%).  Large surface area of the relatively permeable conjunctiva 
explains this result that is in line with previous results with pilocarpine (Thombre and Himmelstein, 
1984; Urtti et al., 1985). Also, intra-ocular absorption through bulbar conjunctiva is possible, but in this 
case the drug will distribute to the iris and ciliary body, not aqueous humour (Ahmed and Patton, 1987, 
1985; Doane et al., 1978) and most of the drug results to the systemic circulation from sub-conjunctival 
space (Ranta et al., 2010). Thus, systemic absorption via conjunctiva is, in any case, 1-2 orders higher 
than ocular delivery to the aqueous humor. Large fraction of the dose enters the systemic circulation from 
the conjunctival fornix (Urtti et al., 1985), but in addition, part of the drug that flows to the nasal mucosa 
and further (such as the pharynx, mouth, and gastrointestinal tract) may be absorbed to the systemic 
circulation (Chang and Lee, 1987; Urtti and Salminen, 1993).  
 
The rate of solution drainage from the ocular surface is difficult to assess and it depends on many factors, 
such as instilled volume, viscosity and induced lacrimation (Chrai et al., 1973; Conrad et al., 1978). 
Drainage may shorten the contact time of the drug with the cornea and conjunctiva decreasing the ocular 
bioavailability even further. However, it should not affect the ratio of corneal and conjunctival drug 
absorption (Fig. 4). Also, in the case of controlled release systems that reside in the conjunctival fornix, 
the drainage factor is less relevant and numbers in Figure 4 may be directly applicable. For eye drops, 
Figure 4 shows the maximal ocular bioavailability values that can be attained.  
 
A broad range of studies has been conducted in order to improve ocular drug bioavailability. The main 
strategies have been to increase corneal drug permeability and to increase drug retention time at the 
surface of the eye (Chang et al., 1988; Chang and Lee, 1987; Kaur et al., 2004; Urtti et al., 1990, 1985; 
Zhang et al., 2004). Corneal drug permeability is expected to improve ocular trans-corneal 
bioavailability, but the effect is less than one would predict.  For new compounds, corneal and 
conjunctival permeability values can be estimated using the QSPR models from this study and Ramsay 












can be attained and potential impact of solution drainage. Thus, this study provides new generalizable 
data and models to augment biopharmaceutical development of new topical ocular medications.   
 
In conclusion, we studied corneal permeability of a compound set with wide chemical space and 
generated a valid QSPR model for prediction of the corneal drug permeation. Follow-up kinetic 
simulations encompassed permeability and flow factors, and provided generalized view on ocular drug 
bioavailability thereby providing tools for ocular drug development.  
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Figure 1. A schematic diagram of the different steps of QSPR model generation for corneal drug 
permeability prediction. 
 
Figure 2. The PCA score plot of the training set (19 compounds) representing the chemical space, which 
was based on 30 different molecular descriptors. 
 
Figure 3. The predicted versus the experimental corneal drug permeability of the external test set drugs. 
The dotted lines represent a 3-fold error line.  
 
Figure 4. Aqueous humour drug bioavailability (F) versus corneal drug permeability (Papp, CO) for the 25 
drugs of the cassette dose. 
 
Figure 5. Conjunctival permeability (Papp, CJ) (Ramsay et al., 2017) versus corneal permeability (Papp, CO) 
(from Table 1) for 25 drugs. Dotted lines represent: same permeability (1:1) or 9 times larger conjunctival 
than corneal permeability (9:1). 
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